CytoSMART Launches Its 1st Fluorescence Live-cell Imaging Microscope

November 3, 2020

CytoSMART Technologies today announced its first fluorescence live-cell imager. The CytoSMART Lux3 FL is a small live-cell imaging microscope equipped with one brightfield and two fluorescent channels (green and red).

CytoSMART notes the device enables researchers to unravel cellular processes in real-time, while the cells are kept in a controlled environment inside a standard cell culture incubator.

CytoSMART states their first fluorescence live-cell imager allows users to track dynamic cellular processes with high specificity by taking high-quality images to create real-time time-lapse movies.


Said Jan-Willem van Bree, CTO at CytoSMART Technologies, “Currently, fluorescent labeling is mostly used as an end-point measurement. However, time-lapse imaging of live cells can give much more information about biological processes. By using automated imaging at regular time intervals, the temporal resolution of the fluorescent data is increased, leading to even more relevant data about the cellular processes.

In this way, researchers can not only determine if a certain process has occurred, but also when it occurred and at what speed. Our customers have been asking us to develop a small and easy-to-use microscope with integrated image analysis of bright-field and fluorescence data. We have listened and made it happen.”

The main features and benefits of the CytoSMART Lux3 FL include:

  • Integrated image analysis of bright-field and fluorescence area or fluorescence object count.
  • Time-lapse movies to investigate the development of cellular processes.
  • Expanded number of variables researchers can analyze in their cell culture using green and red fluorescence.
  • Remote data accessibility via the CytoSMART Cloud with a smartphone, tablet, or laptop outside the lab.
  • Portable, easy-to-use, and incubator friendly live-cell imager.

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.